Anti-diabetes composition patent awarded to Akesis

The PTO has issued a new patent to Akesis Pharmeceuticals for compositions and methods of treatment for diabetes and other glucose metabolism disorders.

"We believe this patent, which combines Akesis' unique formula of anti-diabetic trace minerals with the widely prescribed sulfonylurea class of medications is an important step in our mission to develop innovative formulations for the treatment of diabetes," said President and CEO Edward B. Wilson. "Given the growing public health burden of diabetes and associated metabolic disorders, we are encouraged by the opportunity for a synergistic effect on improved glycemic control offered with this newly patented formulation."